News ImmuneRegen NewsImmuneRegen BioSciences Announces Material Transfer Agreement with HemoGenix(R)January 28, 2008 6:30 AM ETImmuneRegen BioSciences, a wholly owned subsidiary of IR BioSciences Holdings, Inc., announces a Materials Transfer Agreement (MTA) with HemoGenix(R), a Contract Research Service Laboratory that provides a 21st-century approach to developing stem cell assays for the biotechnology and pharmaceutical industry. Their high-throughput, cost-effective technology imparts standardization of stem cell assays, making HemoGenix a valuable collaborator. As part of the agreement, ImmuneRegen will ship its therapeutic candidate Homspera(R) for testing using a number of proprietary tools developed and validated by HemoGenix. HemoGenix will explore the potential of Homspera to stimulate hematopoietic stem cell proliferation and differentiation using their instrument-based ATP bioluminescence technology. By combining a traditional approach for examining stem cell differentiation with a fluorescent tool for measuring proliferation, HemoGenix provides a way to standardize and validate the widely-used stem cell colony-forming cell differentiation assay. Earlier studies performed by ImmuneRegen have shown the ability of Homspera to modify the number of leukocytes circulating in the blood of animals exposed to lethal and sub lethal doses of ionizing radiation. Additional studies are underway to better understand this activity and explore potential therapeutic capabilities in fields as diverse as cancer, immunological disorders, wound healing, regenerative medicine and radioprotection. The agreement with HemoGenix highlights ImmuneRegen's continued progress in its research and development efforts. ImmuneRegen has recently announced research initiatives with a number of major partners in the biotechnology industry, and has sourced $3 million of capital to continue Homspera product development. Commenting on the announcement, Michael Wilhelm, President and Chief Executive Officer of IR Biosciences, said, "We are thrilled to have finalized this agreement with HemoGenix, a company that has taken the colony forming assay for stem cells and made it quantitative. Stem cell research is a major component of our efforts to identify and commercialize potential applications for Homspera. Data collected from the HemoGenix study will provide further evidence for Homspera activity on stem cells." About HemoGenix, Inc. HemoGenix(R) was the first company to provide a fully standardized ATP-based, in vitro bioluminescence assay system designed specifically as an alternative to, and in most cases a replacement for, the colony-forming cell (CFC) assay used to detect stem and progenitor cells of the blood-forming system. Since it's founding in 2000, HemoGenix(R) has developed its own portfolio of proprietary assays for basic research, toxicity, safety and risk assessment for the biopharmaceutical and environmental arenas and quality control assays for stem cell transplantation processing laboratories. HemoGenix(R) produces and sells its assay platforms directly or through its distributors worldwide. About ImmuneRegen BioSciences, Inc.a wholly owned subsidiary of IR BioSciences Holdings, Inc., (OTC BB:IRBS.OB - News) is a development-stage biotechnology company focused on the research, development and licensing of Homspera® and its derivatives. Homspera is an adult stem cell active compound that in study results has been shown to regenerate and strengthen the immune system and enhance wound healing. Viprovex®, a derivative of Homspera, is being developed for potential use against infectious diseases as a stand-alone or combination therapy and as a vaccine adjuvant. To advance its mission, the Scottsdale, Arizona based company has forged numerous study partnerships with industry and academic leaders, including Celgene Cellular Therapeutics, HemoGenix, Lovelace Respiratory Research Institute and Virion Systems. For more information, please visit www.immuneregen.com. Statements about ImmuneRegen's future expectations, including statements about the potential use and scientific results for ImmuneRegen's drug candidates, science and technology, and all other statements in this press release other than historical facts, are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Securities Litigation Reform Act of 1995. ImmuneRegen intends that such forward-looking statements be subject to the safe harbors created thereby. These future events may not occur as and when expected, if at all, and, together with ImmuneRegen's business, are subject to various risks and uncertainties. ImmuneRegen's actual results could differ materially from expected results as a result of a number of factors, including the uncertainties inherent in research and development collaborations, pre-clinical and clinical trials and product development programs (including, but not limited to the fact that future results or research and development efforts may prove less encouraging than current results or cause side effects not observed in current pre-clinical trials), the evaluation of potential opportunities, the level of corporate expenditures and monies available for further studies, capital market conditions, and others set forth in ImmuneRegen's periodic report on Form 10-Q for the three months ended June 30, 2008 and on Form 10-KSB for the year ended December 31, 2007 as filed with the Securities and Exchange Commission. There are no guarantees that any of ImmuneRegen's proposed products will prove to be commercially successful. ImmuneRegen undertakes no duty to update forward-looking statements. Contact: or
### Copyright © 2003-2008, ImmuneRegen Biosciences, Inc. All rights reserved. |
|